NDAORALSOLUTIONPriority Review
Approved
Mar 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
NORVIR (ritonavir) by AbbVie is [see microbiology ( ) ] . First approved in 1996.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORVIR (ritonavir) is an oral protease inhibitor solution approved in 1996 for HIV treatment. It works by inhibiting HIV protease, preventing viral replication and reducing viral load. Ritonavir is predominantly used as a pharmacokinetic booster for other antiretroviral agents rather than as monotherapy.
$0.753MPart D
LOE ApproachingDeclining
Declining commercial footprint with minimal Part D spending signals a mature, specialist-focused product with limited growth opportunities and likely reduced team headcount.
Mechanism of Action
[see Microbiology ( ) ] .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
8 enrolled
HIV Infections
The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients
55 enrolled
HIV Infections
The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
100 enrolled
HIV Infections
A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children
60 enrolled
HIV Infections
Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People
56 enrolled
HIV Infections
Worked on NORVIR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.